Research programme: personalised systemic lupus erythematosus therapeutics - Berg Pharma/Medical University of South CarolinaAlternative Names: Systemic lupus erythematosus therapeutics - Berg Pharma/Medical University of South Carolina
Latest Information Update: 19 May 2014
At a glance
- Originator Berg Pharma; Medical University of South Carolina
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Systemic lupus erythematosus